Opendata, web and dolomites


Armoring multifunctional T cells for cancer therapy

Total Cost €


EC-Contrib. €






 ARMOR-T project word cloud

Explore the words cloud of the ARMOR-T project. It provides you a very rough idea of what is the project "ARMOR-T" about.

expansion    receptors    provision    critically    poor    activation    limited    efficacy    treatment    untreatable    basis    immune    came    powerful    prove    one    armor    solid    safety    clinical    treatments    tumor    melanoma    chemokine    generation    overcome    gene    tackling    group    preclinical    adoptive    integrate    devoid    treat    translated    tumors    suppressive    besides    realise    breast    toxic    platform    local    editing    disease    portfolio    otherwise    focussed    sufficient    suppression    forced    insufficient    pioneering    pancreatic    models    synergistic    act    few    ground    expression    infiltration    made    engineering    molecules    protocol    innovative    subsequently    tackle    antibody    therapies    cancer    mode    action    diseases    site    calls    breaking    date    migratory    therapy    unsuccessful    deletion    cell    simultaneous    rationale    unpublished    unaddressed    activating    entities    activated    prognosis    position    colon    synergy    modular    cellular    limitations    combination    panel    previously    places    indications    feasibility   

Project "ARMOR-T" data sheet

The following table provides information about the project.


Organization address
postcode: 80539

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙636˙710 €
 EC max contribution 1˙636˙710 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2023-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Adoptive T cell therapy (ACT) is a powerful approach to treat even advanced cancer diseases where poor prognosis calls for innovative treatments. However ACT is critically limited by insufficient T cell infiltration into the tumor, T cell activation at the tumor site and local T cell suppression. Few advances have been made in the field to tackle these limitations besides increasing T cell activation. My group has focussed on these unaddressed issues but came to realise that tackling these one by one will not be sufficient. I have developed a panel of unpublished chemokine receptors and innovative modular antibody-activated receptors which have the potential to overcome the limitations of ACT against solid tumors. This ground-breaking portfolio places my group in the unique position to address combination of synergistic receptors and enable cellular therapies in previously unsuccessful indications. My project will provide the rationale for provision of an effective cancer treatment. The goal is to develop the next generation of ACT through T cell engineering both by forced expression of migratory and activating receptors and simultaneous deletion of immune suppressive molecules by gene editing. ARMOR-T will provide the basis for further preclinical and clinical development of a pioneering cellular product devoid of the limitations of available products to date. I will prove 1) synergy between migratory and modular activating receptors, 2) feasibility to integrate gene editing into a T cell expansion protocol, 3) synergy between gene editing, migratory and modular receptors and 4) efficacy, safety and mode of action. The main work of the project will be carried out in models of pancreatic cancer. The ARMOR-T platform will subsequently be translated to other cancer entities where response to ACT is likely such as melanoma, breast or colon cancer, providing less toxic and more effective therapies to otherwise untreatable disease.


year authors and title journal last update
List of publications.
2017 Cornelia Voigt, Peter May, Adrian Gottschlich, Anamarija Markota, Daniel Wenk, Inga Gerlach, Sebastian Voigt, Georgios T. Stathopoulos, Kristina A. M. Arendt, Constanze Heise, Felicitas Rataj, Klaus-Peter Janssen, Melanie Königshoff, Hauke Winter, Isabelle Himsl, Wolfgang E. Thasler, Max Schnurr, Simon Rothenfußer, Stefan Endres, Sebastian Kobold
Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth
published pages: 12994-12999, ISSN: 0027-8424, DOI: 10.1073/pnas.1705165114
Proceedings of the National Academy of Sciences 114/49 2019-10-17
2018 Felicitas Rataj, Fabian B. T. Kraus, Michael Chaloupka, Simon Grassmann, Constanze Heise, Bruno L. Cadilha, Peter Duewell, Stefan Endres, Sebastian Kobold
PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.01955
Frontiers in Immunology 9 2019-10-17
2019 Gabriela M Wiedemann, Celina Aithal, Angelina Kraechan, Constanze Heise, Bruno L Cadilha, Jin Zhang, Peter Duewell, Robert Ballotti, Stefan Endres, Corine Bertolotto, Sebastian Kobold
Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma
published pages: 350-360, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2018.10.014
Translational Oncology 12/2 2019-10-17
2018 Anamarija Markota, Stefan Endres, Sebastian Kobold
Targeting interleukin-22 for cancer therapy
published pages: 2012-2015, ISSN: 2164-5515, DOI: 10.1080/21645515.2018.1461300
Human Vaccines & Immunotherapeutics 14/8 2019-10-17
2019 Sebastian Kobold
Innate and adaptive immunity combined for cancer treatment
published pages: 1087-1088, ISSN: 0027-8424, DOI: 10.1073/pnas.1820166116
Proceedings of the National Academy of Sciences 116/4 2019-10-17
2019 Diana Darowski, Sebastian Kobold, Christian Jost, Christian Klein
Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells
published pages: 621-631, ISSN: 1942-0870, DOI: 10.1080/19420862.2019.1596511
mAbs 11/4 2019-10-17
2019 Stefan Stoiber, Bruno L. Cadilha, Mohamed-Reda Benmebarek, Stefanie Lesch, Stefan Endres, Sebastian Kobold
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
published pages: 472, ISSN: 2073-4409, DOI: 10.3390/cells8050472
Cells 8/5 2019-10-17
2019 Mohamed-Reda Benmebarek, Clara Karches, Bruno Cadilha, Stefanie Lesch, Stefan Endres, Sebastian Kobold
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
published pages: 1283, ISSN: 1422-0067, DOI: 10.3390/ijms20061283
International Journal of Molecular Sciences 20/6 2019-10-17
2019 Stephan Kruger, Matthias Ilmer, Sebastian Kobold, Bruno L. Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W. Renz, Jan G. D’Haese, Hans Schloesser, Volker Heinemann, Marion Subklewe, Stefan Boeck, Jens Werner, Michael von Bergwelt-Baildon
Advances in cancer immunotherapy 2019 – latest trends
published pages: , ISSN: 1756-9966, DOI: 10.1186/s13046-019-1266-0
Journal of Experimental & Clinical Cancer Research 38/1 2019-10-17
2019 Xiao Liu, Junjian Li, Bruno Loureiro Cadilha, Anamarija Markota, Cornelia Voigt, Zhe Huang, Peter P. Lin, Daisy D. Wang, Juncheng Dai, Gisela Kranz, Anna Krandick, Darko Libl, Horst Zitzelsberger, Isabella Zagorski, Herbert Braselmann, Min Pan, Sibo Zhu, Yuanchi Huang, Sebastian Niedermeyer, Christoph A. Reichel, Bernd Uhl, Daria Briukhovetska, Javier Suárez, Sebastian Kobold, Olivier Gires, Hong
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis
published pages: eaav4275, ISSN: 2375-2548, DOI: 10.1126/sciadv.aav4275
Science Advances 5/6 2019-10-17
2019 Clara H. Karches, Mohamed-Reda Benmebarek, Moritz L. Schmidbauer, Mathias Kurzay, Richard Klaus, Martina Geiger, Felicitas Rataj, Bruno L. Cadilha, Stefanie Lesch, Constanze Heise, Ramona Murr, Johannes vom Berg, Martin Jastroch, Daniel Lamp, Jian Ding, Peter Duewell, Gerhard Niederfellner, Claudio Sustmann, Stefan Endres, Christian Klein, Sebastian Kobold
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
published pages: 5890-5900, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-3927
Clinical Cancer Research 25/19 2019-10-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARMOR-T" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ARMOR-T" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth Perspective

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More